Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “STX-0712 is IV administered every 21 days until the patient discontinues treatment.”In the company’s words, NCT06950034 on ClinicalTrials.gov
- Tested for
- Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Refractory Chronic Myelomonocytic Leukemia, CMML, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML) and 4 more
- Main trialPhase 1
- “This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.”In the company’s words, NCT06950034 on ClinicalTrials.gov
Other drugs for Chronic Myelomonocytic Leukemia
- ASTX030Taiho · Phase 2/3
- ASTX727Taiho · Phase 3
- TuspetinibAptose Biosciences Inc. · Phase 1/2
- BexmarilimabFaron Pharmaceuticals Ltd · Phase 1/2
- S241656Servier · Phase 1/2
- EP0042Ellipses Pharma · Phase 1/2
Coming up1
- 31 DecPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 31 Dec 2026 | A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026